Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40
- PDF / 929,541 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 62 Downloads / 191 Views
ORIGINAL ARTICLE – CANCER RESEARCH
Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40‑µm doxorubicin‑eluting microspheres Katharina Carolin Albrecht1 · René Aschenbach1 · Ioannis Diamantis1 · Niklas Eckardt1 · Ulf Teichgräber1 Received: 2 March 2020 / Accepted: 19 August 2020 © The Author(s) 2020
Abstract Purpose To evaluate the response rate and safety of superselective drug-eluting beats transarterial chemoembolization (DEBTACE) with doxorubicin-loaded 40-µm microspheres in patients with hepatocellular carcinoma (HCC). Methods One hundred and forty-one treatments with doxorubicin-loaded 40-µm microspheres in 83 patients between 2012 and 2017 were retrospectively evaluated. Images of the treated lesions were analyzed before and after each treatment according to mRECIST (modified Response Evaluation Criteria in Solid Tumors). Therapy response (complete response [CR] + partial response [PR]) and disease control (CR + PR + stable disease [SD]) rates were determined, and the correlation between the longitudinal axis (longest diameter of the tumor) and volume was investigated using a newly developed software for systematic tumor response assessment. Additional endpoints were progression-free survival (PFS) and time to progression (TTP). Results In the target tumors, a therapy response rate of 63.1% and a disease control rate of 95.7% were achieved. There was a good correlation between the measurement of the longitudinal axis and volume of the measured lesion (r value, 0.954). The median PFS was 2.23 months, and the median TTP was 5.91 months. The serious adverse event rate (SAE) was 10.64%. Conclusion Superselective DEB-TACE with 40-µm sized Embozene Tandem™ can be considered an effective and safe treatment, given the number of procedure-related complications. Keywords Transarterial chemoembolization · TACE · Hepatocellular carcinoma · Doxorubicin-eluting microspheres
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00432-020-03370-z) contains supplementary material, which is available to authorized users. * Ulf Teichgräber [email protected]‑jena.de Katharina Carolin Albrecht [email protected] René Aschenbach [email protected]‑jena.de Ioannis Diamantis [email protected]‑jena.de Niklas Eckardt [email protected]‑jena.de 1
Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Jena IDIR, Am Klinikum 1, 07747 Jena, Germany
Abbreviations DEB Drug-eluting beats TACE Transarterial chemoembolization HCC Hepatocellular carcinoma CR Complete response PR Partial response SD Stable disease PFS Progression-free survival TTP Time to progression SAE Serious adverse event MRI Magnetic resonance imaging CT Computed tomography AFP Alpha-fetoprotein PD Progressive disease MPP Mean value of positive pixels UPP Uniformity of distribution of positive pixels mRECIST Modified response evaluation criteria in solid tumors AE Adve
Data Loading...
